Galcanezumab Shows Persisting Effects in Chronic, Episodic Migraine
Patients with episodic and chronic migraine were randomly assigned to receive subcutaneous injections of galcanezumab or placebo.
|The following article is part of conference coverage from the PAINWeek 2018 conference in Las Vegas, Nevada. Clinical Pain Advisor's staff will be reporting breaking news associated with research conducted by leading experts in pain medicine. Check back for the latest news from PAINWeek 2018.|
LAS VEGAS — Galcanezumab may provide clinically meaningful relief from episodic migraine and chronic migraine, according to a study presented at PAINWeek 2018, held in Las Vegas, Nevada, September 4 to 8.
The study included one study that recruited patients with episodic migraine (4 to 14 migraine headache days and ≥2 migraine attacks per month; n=1773) and another study that enrolled patients with chronic migraine (ie, with >15 headache days per month for >3 months and ≥8 migraine headache days per month; n=1113). Patients with episodic and chronic migraine were randomly assigned to receive subcutaneous injections of galcanezumab 120 mg/month (n=444 and n=278, respectively), galcanezumab 240 mg/month (n=435 and n=277, respectively), or placebo (n=894 and n=558, respectively).
The percentage of patients who achieved maintenance of ≥50% response (≥50% reduction in monthly mean headache days from baseline) for 3 and 6 consecutive months in patients with episodic migraine and 3 months in participants with chronic migraine was evaluated in all treatment groups. Greater percentages of patients with episodic migraine who received galcanezumab at 120 mg and 240 mg were found to achieve a ≥50% response compared with placebo for ≥3 consecutive months (41.5% and 41.1%, respectively vs 21.4%; P <.001 for both) and 6 consecutive months (19.0% and 20.8%, respectively vs 8.0%; P <.001 for both).
Greater percentages of patients with chronic migraine treated with galcanezumab vs placebo were found to maintain a ≥50% response for 3 months (galcanezumab 120 mg, 16.8%; galcanezumab 240 mg, 14.6%; placebo, 6.3%; P <.001 for all).
Aurora SK, Zhang Q, Stauffer VL, Daniele MI. Persistence of effect of galcanezumab in patients with episodic or chronic migraine: phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2 and REGAIN studies. Presented at: PAINWeek 2018, September 4-8, 2018, Las Vegas, NV. Poster 108.
For more coverage of PAINWeek 2018, click here.